Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | FBP1 | P09467 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | EIF4E | P06730 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408882 | 0.88 | CYP1A2 (0.57) | CYP1A2ABCB1MAPTMEN1KMT2A | |
| SCHEMBL4413254 | 0.88 | RXRA (0.54) | CYP1A2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2436193 | 0.85 | CYP1A2 (0.63) | CYP1A2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4014665 | 0.85 | CYP1A2 (0.63) | CYP1A2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4409756 | 0.84 | CYP1A2 (0.65) | CYP1A2FBP1ABCB1NPC1RAB9A | |
| SCHEMBL5233562 | 0.83 | NPC1 (0.47) | CYP1A2FBP1ABCB1MAPTMEN1 | |
| SCHEMBL6225598 | 0.81 | FBP1 (0.55) | FBP1ABCB1MAPTEIF4ENPC1 | |
| SCHEMBL4407751 | 0.79 | CYP1A2 (0.52) | CYP1A2ABCB1ALDH1A1EIF4ENPC1 | |
| SCHEMBL6225602 | 0.79 | ABCB1 (0.50) | FBP1ABCB1MAPTALDH1A1EIF4E | |
| SCHEMBL4408350 | 0.78 | FBP1 (0.52) | FBP1MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-08-31 | — | — | US | disclosed |
| US-7098236-B2 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-03-23 | — | — | US | disclosed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20010056094-A1 | Anticarcinogenic agents | TANG PENG CHO (US) | 2001-12-27 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6316429-B1 | ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6313158-B1 | THERAPY AND PROPHYLAXIS OF CANCER | SUGEN, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056094-A1 | Anticarcinogenic agents | GSTK1, CDC42BPG, GLS | CYP1A2 976/4885FBP1 1944/4885ABCB1 924/4885 |
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | CYP1A2 3652/4885FBP1 2400/4885ABCB1 2905/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | CYP1A2 3652/4885FBP1 2400/4885ABCB1 2905/4885 |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | CYP1A2 3652/4885FBP1 2400/4885ABCB1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.